The identification of FLT3-ITD, NPM1, and IDH1/2 have profoundly shifted diagnostic and therapeutic paradigms in AML, while data regarding the potential impact on prognosis and options for therapeutic targeting remain sparse for other somatic mutations. This evidence concerns the gene IDH1 and acute myeloid leukemia.